United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News Gilead Sciences acquires RP-3467 from Repare Therapeutics to strengthen synthetic lethality pipeline Gilead buys RP-3467 from Repare for up to $30M, boosting Repare’s shareholder payout ahead of its Xeno acquisition. Find out what this means for oncology. byVenkateshJanuary 2, 2026